Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific

Executive Summary

Starts & Stops is a regular feature highlighting Medtech Insight's monthly picks of noteworthy clinical trial announcements, initiations, completions, and suspensions. The list for December is headlined by announcements on Edwards' transcatheter valve technologies. Meanwhile, MValve, a company Boston Scientific has invested in, is not going forward with a planned trial of its MValve dock device with Boston Scientific's Lotus valve, which is currently off the market.

Advertisement

Related Content

Medtronic Confident Renal Denervation Trial Will Work This Time
CRT 2018: Late-Breakers Feature Sapien MR, Selution DCB, Low-Risk TAVR, and Radial Access PCI
Boston Scientific Hooks In Millipede, But Still Trailing Behind In Mitral Valve Race
Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals
Edwards Adds To Wide Range Of Approaches To Mitral Repair
LOTUS Wilts? Analysts Pessimistic Over Further Delays in Boston Scientific's TAVR Return
ESC 2017: Renal-Denervation Redux? Medtronic Plans A New Pivotal Study Following Positive Data
Earnings Winners and Losers: JNJ, MMSI, ABT, ZBH, SNN, EW, Plus Round-Up
Deals Shaping the Medical Industry, August 2016
Transcatheter Mitral Valve Therapy: Opportunities And Challenges

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel